CVS Health Stock Performance Amid Legal Resolution and AI Launch
Article Content
- •CVS Health stock is up 16.65% year-to-date despite recent pullbacks.
- •The company resolved a significant $315 million opioid-related legal case.
- •Analysts consider CVS Health undervalued with a fair value estimate of $124.
CVS Health has gained attention following the launch of its Health100 AI platform and the resolution of a $315 million opioid-related legal case. The company's stock price increased by 16.65% year-to-date, despite a 12.70% decline over the past 90 days. CVS reported improved Q2 2026 profitability, raising its full-year guidance twice this year. The stock is currently trading at $93.47, which is considered undervalued compared to a fair value estimate of $124. Analysts project adjusted EPS of at least $8.44 in 2027, indicating potential for further growth. The company has also expanded its GLP-1 programs, contributing to its positive outlook.
Ask AI about this cluster
Answers cite the sources they use
Timeline
More articles in this cluster (2)
Following this threat?
Track CVS Health in your own feed — you're alerted when they show up in new reporting, leak sites or exploitation.
Free account · no card needed